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Reduced Macrophage Apoptosis Is Associated With Accelerated
 
Atherosclerosis in Low-Density Lipoprotein Receptor–Null Mice
 
June Liu, Douglas P. Thewke, Yan Ru Su, MacRae F. Linton, Sergio Fazio, Michael S. Sinensky 
Objective—The majority of apoptotic cells in atherosclerotic lesions are macrophages. However, the pathogenic role of 
macrophage apoptosis in the development of atherosclerosis remains unclear. Elevated expression of Bax, one of the 
pivotal proapoptotic proteins of the Bcl-2 family, has been found in human atherosclerotic plaques. Activation of Bax 
also occurs in free cholesterol–loaded and oxysterol-treated mouse macrophages. In this study, we examined the effect 
of Bax deficiency in bone marrow– derived leukocytes on the development of atherosclerosis in low-density lipoprotein 
receptor–null (LDLR-/-) mice. 
Methods and Results—Fourteen 8-week-old male LDLR-/- mice were lethally irradiated and reconstituted with either 
wild-type (WT) C57BL6 or Bax-null (Bax-/-) bone marrow. Three weeks later, the mice were challenged with a 
Western diet for 10 weeks. No differences were found in the plasma cholesterol level between the WT and Bax-/-
group. However, quantitation of cross sections from proximal aorta revealed a 49.2% increase (P=0.0259) in the mean 
lesion area of the Bax-/- group compared with the WT group. A 53% decrease in apoptotic macrophages in the 
Bax-/- group was found by TUNEL staining (P<0.05). 
Conclusions—The reduction of apoptotic activity in macrophages stimulates atherosclerosis in LDLR-/- mice, which is 
consistent with the hypothesis that macrophage apoptosis suppresses the development of atherosclerosis. (Arterioscler 
Thromb Vasc Biol. 2005;25:174-179.) 
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Apoptosis, also called programmed cell death, plays a critical role in tissue development and maintenance of homeostasis 
within multicellular organisms. Two different pathways have 
been identified: mitochondrial pathway and death receptor path­
way. The multidomain Bcl-2 family members, consisting of 
antiapoptotic (Bcl-2 and Bcl-xL) and proapoptotic (Bax and Bak) 
proteins, play pivotal roles in the mitochondrial apoptotic path­
way.1 Activation of Bax or Bak has been reported to be the 
essential gateway to mitochondrial dysfunction and cell death.2,3 
In healthy cells, Bax is predominantly a cytosolic monomer. On 
stimulation, it undergoes conformational changes and translo­
cates to the outer mitochondrial membrane or endoplasmic 
reticulum where it oligomerizes.4–6  In the well-described mito­
chondrial death pathway, Bax or Bak permeabilize the outer 
mitochondrial membrane, allowing the efflux of cytochrome c 
and other apoptosis regulatory proteins into the cytosol.1,7,8 
Suggestive of the central physiological role for Bax in pro­
grammed cell death, Bak-null mice fail to show any develop­
mental defects9; however, Bax-deficient mice displayed hyper­
plasia of thymocytes and B cells as well as abnormalities in the 
development of the reproductive system.10 
During the past 10 years, apoptosis in atherosclerotic 
lesions has been broadly reported. All 3 of the major cell 
types found in atherosclerotic lesions (eg, macrophages, 
smooth muscle cells [SMCs], and endothelial cells) can 
undergo apoptosis. Given the complexity of atherosclerotic 
plaque, apoptosis in these different cell types may play 
different roles in atherogenesis.11,12 
Macrophages are found in all stages of atherosclerosis. The 
expression of a variety of genes and their proteins which affect 
lipoprotein metabolism and cholesterol accumulation has been 
shown to influence the progression of atherosclerosis.13,14 On 
activation, macrophages generate a large number of cytokines 
and growth factors that regulate lesion development in both 
paracrine and autocrine manners.14 –16 The majority of apoptotic 
cells in atherosclerotic lesions are macrophages localized near 
the necrotic areas of advanced lesions.17 Overexpression of Bax 
and other related apoptotic proteins has been found in human 
atherosclerotic plaques.18 –20 Bax activation has been shown to 
occur during apoptosis resulting from free cholesterol loading of 
macrophages21 or after treatment of macrophages with oxys­
terols,22 which are cytotoxic components of oxidized low-
density lipoprotein (LDL).23 Induction of apoptosis by oxys­
terols in a macrophage cell line is greatly attenuated when Bax 
is subjected to small interfering RNA knockdown regardless of 
the normal expression of Bak.22 
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Although foam cell apoptosis has long been hypothesized to 
contribute to the development of lipid core,17,24 the role of 
macrophage apoptosis in atherosclerosis remains unclear. Mac­
rophage death may reduce the production of growth factors and 
inflammatory cytokines, which in turn may impede the devel­
opment of atherosclerosis. On the other hand, loss of macro-
phages may promote proatherogenic factors, such as decreased 
production of apoE and reduced scavenging of toxic substances 
(ie, oxidized LDL [oxLDL]).25–27 
The goal of these studies is to investigate the consequences of 
macrophage apoptosis in atherogenesis. Because of the generally 
accepted role of Bax in apoptosis as well as the specific 
observations implicating Bax activation in macrophage apopto­
sis associated with atherogenesis, we chose to examine the effect 
of Bax expression on atherosclerosis. Based on previous reports 
that the expression of LDL receptor in bone marrow– derived 
leukocytes would not affect the progression of atherosclerosis in 
LDL receptor–null (LDLR-/-) mice,28 –30 our objective was 
accomplished by transplanting atherosclerosis-susceptible 
LDLR-/- mice with Bax-positive or -deficient bone marrow. 
Materials and Methods 
Mice 
Both male LDLR-/- receipt mice (B6.129S7-Ldlrtm1Her) and Bax­
null (Bax-/- donor mice (B6.129X1-Baxtm1Sjk) are from The Jack­
son Laboratory (Bar Harbor, Me) and on C57BL6 background. All 
mice were maintained in microisolator cages on autoclaved rodent 
chow containing 4.5% fat (Purina Mills Inc) and autoclaved acidified 
water. Experimental protocols were performed according to the 
regulations of the Vanderbilt University Animal Care Committee. 
Bone Marrow Transplantation 
One week before and 2 weeks after transplantation, all recipient 
LDLR-/- mice were given acidified water containing 5 mg/L 
neomycin and 25 000 U/L polymyxin B sulfate (Monarch Pharma­
ceuticals). Eight-week-old male LDLR-/- mice received 10 Gy 
whole-body irradiation from a cesium ' source and were trans­
planted with 5X106 bone marrow cells from wild-type (WT) 
C57BL6 or Bax-/- donor mice as described previously.25 Three 
weeks later they were fed a Western diet (21% fat and 0.15% 
cholesterol; Harlan Teklad) for 10 weeks. 
Determination of Chimerism by Western Blotting 
Before euthanization, peritoneal macrophages were collected from 4 
recipient mice randomly chosen from each group. Protein samples 
(20 Jg each) were separated on NuPage 10% Bis-Tris Gel (Invitro­
gen) and transferred onto Hybond-P polyvinylidene fluoride mem­
brane (Amersham Biosciences). Bax protein was detected using 
rabbit polyclonal anti-Bax (Upstate Biotech, Lake Placid, NY). The 
same blot was stripped and reprobed using rabbit polyclonal anti-f 
actin (AbCam, Cambridge, Mass). 
Serum Cholesterol, Triglyceride, Lipoprotein 
Analysis, and Peripheral White Blood Cell Count 
Blood samples were collected by retro-orbital venous plexus punc­
ture after overnight fasting. Serum was separated by centrifugation at 
10 000g for 10 minutes at 4°C. Total cholesterol and triglycerides 
were determined using Cholesterol Reagent and Triglycerides GPO 
reagent kits (Raichem). Serum from randomly chosen mice was also 
subjected to fast-performance liquid chromatography (FPLC) anal­
ysis of lipoprotein as described.31 
Blood smears were prepared 12 weeks after bone marrow transplan­
tation and subjected to Quick-Diff staining (Biochemical Sciences). 
White blood cells were differentiated by scoring a minimum of 200 
cells. 
Quantitation of Arterial Lesions 
After 10 weeks on Western diet, mice were euthanized and perfused 
with 20 mL of PBS through the left ventricle. Heart and proximal 
aorta were embedded in OCT and snap-frozen in liquid nitrogen 
(LN2). Every other 10-Jm cross section was collected starting from 
the end of the aortic sinus as described.32 A total of 15 cryosections 
from each mouse were stained with oil red O (Sigma) and counter-
stained with Mayer’s hematoxylin (Electron Microscopy Sciences). 
Quantitative analysis of the lesion area was performed using KS300 
Imaging System Version 3.0 (Carl Zeiss Vision GmbH). 
Immunohistochemistry 
Serial 5-Jm cryosections from proximal aortas were fixed in acetone 
at -20°C for 10 minutes and stained with either rat anti-mouse 
macrophages/monocyte marker MOMA-2 (Accurate Chemical & 
Scientific Corp, Westbury, NY) and biotinylated mouse anti-rat 
IgG2b antibody (BD Biosciences Pharmingen, San Diego, Calif), or 
smooth muscle a-actin epitope-specific rabbit antibody (Laboratory 
Vision, Fremont, Calif) and biotin labeled goat anti-rabbit IgG 
polyclonal antibody (BD Biosciences Pharmingen). After the inac­
tivation of endogenous peroxidase in 0.3% H2O2/methanol for 30 
minutes, the sections were incubated with streptavidin– horseradish 
peroxidase complex (BD Biosciences Pharmingen), developed with 
diaminobenzidine-enhanced liquid substrate system (Sigma), and 
then counterstained with methyl green (Vector Laboratories). The 
staining was analyzed using AxioVision 3.1 connected with Axio­
plan2 imaging microscope (Carl Zeiss Vision GmbH). 
TUNEL Studies 
An in situ cell death detection POD kit (Roche Applied Science) was 
used with slight modification. Five-micron cryosections were pre­
treated with 3% citric acid, fixed, and labeled according to manu­
facturer’s instruction. After development using diaminobenzidine, 
all sections were counterstained with methyl green. Four serial 
sections from each mouse were stained. The same protocol was used 
for TUNEL of peritoneal macrophages cultured in Laboratory-Tek 
chamber slides (Nalge Nunc International). TUNEL-positive cells 
were counted in 10 fields under light microscope (X400). 
Caspase-3 Activity Assay 
Peritoneal macrophages were isolated 3 days after IP injection with 
1.5 mL of 6% thioglycollate. After overnight incubation in DMEM 
supplemented with 5% FBS, cells were treated with 10 Jg/mL 
7-ketocholesterol (7-KC) for 12 hours. The caspase-3 activity was 
assayed using CPP32/caspase-3 fluorometric protease assay kit from 
Chemicon International Inc and read by Fusion microplate reader 
(Perkin–Elmer). The relative fluorescent unit was normalized to the 
protein concentration of the sample. 
Statistics 
Nonparametric Mann–Whitney test was used to measure the statis­
tical differences in lesion area. Student t test assuming 2 samples 
with equal variances was used in other analyses. P<0.05 was 
considered to be statistically significant. 
Results 
Bax-Deficient Mouse Peritoneal Macrophages 
Display Reduced Levels of Apoptosis In Vitro on 
Stimulation by Oxysterols or Staurosporine 
Expression of the multidomain proapoptotic proteins, Bax 
and/or Bak, are required for the activity of the mitochondrial 
apoptosis pathway.2 Various oxysterol components of oxLDL 
have been shown to largely account for the apoptotic activity 
of oxLDL and have been hypothesized to play a role in 
atherogenesis.23 Oxysterol-induced apoptosis proceeds 
through the mitochondrial death pathway.22,23 
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Figure 1. Bax-deficient mouse peritoneal macrophages display 
reduced apoptosis in vitro. A, Caspase-3 activity assay after 
12-hour treatment with 7-KC. Relative fluorescent unit (RFU) 
was normalized to protein concentrations. Data represent 3 
independent experiments. B, TUNEL staining after the treatment 
with 25-hydroxycholesterol (25-OHC) for 40 hours or staurospo­
rine (STS) for 21 hours. *P<0.05 compared with the WT group. 
To examine the impact of Bax deficiency on apoptosis in 
mouse peritoneal macrophages, we assayed the caspase-3 activ­
ity in macrophages isolated from WT C57BL6 and Bax knock­
out mice after 12-hour treatment with 10 Jg/mL 7-KC, an 
important cytotoxic component of oxLDL.23 The caspase-3 
activity was significantly lower in Bax-/- macrophages com­
pared with that in WT macrophages (P<0.05; Figure 1A). 
Consistent with this result, Bax-/- macrophages also showed 
less TUNEL-positive cells compared with the WT cells after 
treatment with either another oxysterol, 25-hydroxycholesterol, 
or staurosporine (STS, Figure 1B). Therefore, consistent with 
prior studies with Bax knockdown cultured cells,22 Bax-/-
mouse peritoneal macrophages are partially resistant to apopto­
sis induced by oxysterols. They are also partially resistant to 
STS, which also acts through the mitochondrial pathway. Partial 
resistance to the STS induction of apoptosis in Bax-deficient 
mouse embryonic fibroblast cells has been reported previously.2 
Reconstitution of LDLR-/- Mice With 
Bax-Deficient Bone Marrow Does Not Affect the 
Plasma Cholesterol and Triglyceride Levels, 
Plasma Lipoprotein Profile, or Peripheral 
Lymphocyte Counts 
As expected, our in vitro studies show that Bax deficiency 
leads to significantly reduced apoptosis in mouse peritoneal 
macrophages in response to agents that activate the mitochon­
drial death pathway. To investigate the role of macrophage 
apoptosis in the development of atherosclerosis, 8-week-old 
LDLR-/- mice (male, n=14 in each group) were lethally 
irradiated and transplanted with 5X106 bone marrow cells 
from WT or Bax-/- donor mice. The reconstitution of 
recipient mice with donor bone marrow– derived hematopoi-
Figure 2. Complete repopulation of recipient mice by donor 
marrow was confirmed by Western blotting. Whole-cell lysates 
were prepared from peritoneal macrophages isolated from 4 
transplants randomly chosen from each group 13 weeks after 
bone marrow transplantation. f-actin was probed as the loading 
control. 
etic cells was determined by Western blotting 13 weeks after 
bone marrow transplantation. Bax protein was detected in the 
peritoneal macrophages isolated from the WT group but not 
in those from the Bax-/- group (Figure 2). The level of 
reconstitution was also determined by polymerase chain 
reaction of the LDLR gene, because both sets of donor bone 
marrow cells were LDLR-positive. Consistently, 8 weeks 
after the bone marrow transplantation, the WT LDLR gene 
was detected in the genomic DNA extracted from the whole 
blood of all mice from both groups. In addition, the mutant 
LDLR gene in both groups was below the detectable level 
after 30 polymerase chain reaction cycles, indicating a 
complete reconstitution of the recipient hematopoietic cells 
by the donor bone marrow cells (data not shown). 
To assess the lipid parameters, plasma samples were collected 
before the start of Western diet as the baseline and every 4 weeks 
thereafter. Bax deficiency in macrophages did not affect the 
plasma cholesterol (Figure 3A) and triglyceride levels (Figure 
3B). Plasma lipoprotein analysis by FPLC did not reveal any 
differences between the 2 groups (Figure 3C). Differential white 
blood cell count 12 weeks after bone marrow transplantation 
revealed no differences in the peripheral lymphocyte counts 
(81.3±2.9% in the WT group and 79.5±8.7% in Bax-/-
group). 
Bax Deficiency in Bone Marrow–Derived 
Leukocytes Stimulates the Development 
of Atherosclerosis 
To examine the influence of Bax deficiency on atherosclero­
sis, all recipient mice were euthanized after 10 weeks on a 
Western diet. The atherosclerotic lesions in the proximal 
aortas were stained with oil red O. Quantitation revealed a 
49.2% increase in the mean cross sectional lesion area 
(Jm2±SEM) in the proximal aortas of Bax-/- group 
(233 800±20 489 Jm2) compared with the control group 
(156 700±20 243 Jm2; Figure 4, P=0.0259). 
To further characterize the atherosclerotic plaque, macro-
phages and SMCs in serial sections were stained with specific 
antibodies (Figure 5). Lesions were classified into 2 types based 
on the prior literature33–35: early lesions mainly composed of 
macrophage-derived foam cells and advanced lesions character­
ized by the presence of SMCs and collagen in the cap area. 
Interestingly, 31% of the lesions in the Bax-/- group, com­
pared with only 17% in the control group, were advanced lesions 
with fibrous caps. These fibrous plaques from both groups were 
larger in size compared to those without SMC staining in the cap 
region, indicating they were in a more developed stage. These 
lesions often contained necrotic cores while observed under 
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Figure 3. Plasma total cholesterol (A) and triglyceride levels (B) 
measured before and every 4 weeks after the beginning of 
western diet. C, Plasma lipoprotein profiles obtained by FPLC 
after 8-week Western diet. 
higher magnification (data not shown). Taken together, our 
studies show that Bax deficiency in bone marrow– derived cells 
stimulates the development of atherosclerosis in LDLR-/-
mice. 
Deficiency of Macrophage Bax Leads to Reduced 
Apoptosis in Atherosclerotic Lesions 
As described above, Bax-/- macrophages display reduced 
levels of apoptosis in vitro. To investigate whether the 
increased lesion area in the Bax-/- transplantation group 
was associated with decreased macrophage apoptotic activity 
in vivo, modified TUNEL was performed on cross sections of 
proximal aortas. The majority of apoptotic cells in the lesions 
were macrophages. Consistent with the proposed role for Bax 
in macrophage apoptosis, the number of apoptotic macro-
phages was decreased by 53% in the Bax-/- group 
(15.3±9.9 per mm2) compared with that of the control group 
(32.5±10.8 per mm2, Figure 6, P<0.05). Interestingly, the 
SMCs in the proximal aorta from Bax-/- group also had 
reduced apoptosis compared with those from WT group 
(8.6±6.3 per mm2 in Bax-/- group and 25.6±10.3 per mm2 
in control group, Figure 6, P<0.05). 
Discussion 
In this study, reconstitution of LDLR-/- mice with Bax-/-
bone marrow resulted in a significant increase in mean lesion 
area as compared with the mice reconstituted with WT bone 
marrow. As expected, fewer apoptotic macrophages were 
Figure 4. Lesion area quantitation in cross sections of proximal 
aortas after 10 weeks on Western diet revealed a 49.2% 
increase in the mean cross-sectional lesion area of Bax-/-
group compared with control group. Each data point represents 
the mean cross-sectional lesion area per mouse; the line repre­
sents the mean value of each group, n=14, P=0.0259 by non-
parametric Mann–Whitney test. 
found in the Bax-/- group, consistent with the hypothesis 
that the increase in lesion size is because of decreased 
apoptotic activity. In addition, higher numbers of advanced 
lesions with fibrous caps were found in the Bax-/- group. 
Our data demonstrate that macrophage apoptosis plays a 
protective role in the development of atherosclerosis. This is 
the first study that directly tests the effect of mitochondrial 
apoptotic pathway on atherogenesis. 
Our in vitro studies showed that the induction of apoptosis by 
oxysterols in Bax-deficient mouse peritoneal macrophages is 
attenuated. This finding is consistent with our previous studies 
demonstrating that small interfering RNA knockdown of Bax 
results in the loss of oxysterol-induced apoptosis.22 Partial 
resistance is to be expected, because the functions of Bax have 
been shown to be redundant with Bak and only cells lacking 
both Bax and Bak are totally defective in the mitochondrial 
pathway.2 
Induction of apoptosis by oxysterol is mediated through the 
mitochondrial death pathway and probably occurs within ath­
erosclerotic lesions.23 However, because of the central role that 
Figure 5. Immunostaining for macrophages in the lesion (A, C) 
and SMCs in the arterial wall and lesion cap area (B, D) in serial 
sections from proximal aorta. A and B, Serial sections from con­
trol group. C and D, Serial sections from Bax-/- group. Scale 
bar=200 Jm. 
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Figure 6. In situ TUNEL staining of proximal aorta sections from 
the control group (A) and the Bax-/- group (B). Arrows indicate 
TUNEL-positive nuclei, scale bar=200 Jm. C, Quantitation of 
TUNEL-positive macrophages and SMCs per mm2 lesion area, 
n=14, *P<0.05 compared with WT group. 
Bax plays in the mitochondrial apoptosis pathway, the reduction 
of apoptosis in atherosclerosis lesions observed in mice trans­
planted with Bax-/- bone marrow would be expected for a 
broad spectrum of apoptotic inducers. For this reason, our 
observations are more relevant to the role of macrophage 
apoptosis in atherogenesis than to the role of any specific 
physiological apoptotic inducer. 
Some prior studies have attempted to determine the role of 
apoptosis in atherogenesis by means of p53-null mice. Macro-
phages deficient in the tumor suppresser protein p53 have been 
reported to enhance atherosclerosis in apoE*3-Leiden transgenic 
mice, which was correlated with a decrease in apoptosis in the 
p53-deficient mice.36 Increased atherosclerosis has also been 
reported in another study using p53-/-apoE-/- mice, al­
though the authors did not find significant change in apoptotic 
cell numbers but, rather, an increase in cell proliferation.37 These 
contradictory results probably reflect the multiple functions of 
p53, which acts to integrate a number of cellular signals to 
regulate either cell cycle arrest or apoptosis rather than acting as 
a specific regulator of the mitochondrial death pathway.38,39 In 
contrast, Bax deficiency directly affects the mitochondrial path­
way, which can be stimulated by various signals including the 
activation of p53. 
In another study of the role of apoptosis in atherosclerosis, 
inhibition of neointimal cell bcl-xL expression, 1 of the antiapo­
ptotic Bcl-2 family members, by transfection with anti–bcl-x 
antisense oligonucleotides was observed to induce apoptosis 
within intimal cells and acute regression of lesions in carotid 
arteries of rabbits.40 However, under these experimental condi­
tions, the cell types that take up the antisense oligonucleotides 
are uncertain. In contrast, the current study is focused on lesion 
macrophages derived from Bax-/- donor bone marrow (Fig­
ures 5 and 6). Our results more specifically demonstrate the 
effect of mitochondrial apoptotic pathway in macrophages on 
the development of atherosclerosis. 
Bcl-2 family proteins also affect the survival of lympho­
cytes.41,42 Bax-deficient mice have been reported to have selec­
tive hyperplasia of lymphoid tissues.10 In searching for any 
additional mechanistic explanation for increased lesion area in 
mice transplanted with Bax-/- bone marrow, we examined the 
peripheral leukocytes in all recipient mice by Quick-Dif staining. 
No difference was found in the peripheral leukocyte content 
between the 2 groups. However, increased inflammation in 
Bax-/- group cannot be excluded, because lesions in this 
group contain a relatively higher number of macrophages, one of 
the mediators of inflammatory response in atherosclerotic 
lesions.14,43 
There are a number of proatherogenic aspects of lesion 
macrophages. Mice deficient in both macrophage colony stim­
ulating factor and apoE (op/apoE) have smaller proximal aortic 
lesions at earlier stages of lesion progression and decreased 
blood monocyte differentials.44 Consistent with this observation, 
IP administration of antibody for the macrophage colony stim­
ulating factor receptor prevents the initial events of atherogene­
sis.45 Therefore, a lowered level of apoptosis in Bax-deficient 
macrophages would also be expected to be proatherogenic by 
certain macrophage-dependent processes, such as increased 
number and/or functions of monocyte-derived macrophages, 
increased growth factor production, cell proliferation, or foam 
cell accumulation.14 
Our observation that mice reconstituted with Bax-/- bone 
marrow have decreased SMC apoptosis is also of interest. 
Although we are unable to distinguish the origin of these SMCs, 
the possibility that these SMCs are derived from Bax-deficient 
bone marrow cannot be excluded according to previous re­
ports.46,47 The increased SMC content in the lesions of Bax-/-
group may also be associated with the interaction between 
Bax-/- macrophages and SMCs. 
In summary, our studies show that the reduced apoptotic 
activity in macrophages because of Bax deficiency promotes the 
development of atherosclerosis, indicating that macrophage 
apoptosis provides a critical self-defense mechanism in sup­
pressing atherosclerosis. Mitochondria-targeting proapoptotic 
drugs have been under broad development for a wide range of 
applications, from cancer chemotherapy, HIV, to organ trans­
plantation.48,49 Our data indicate that the mitochondrial apoptosis 
pathway in vascular macrophages may be an attractive target for 
the prevention and treatment of atherosclerosis. 
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